Table 4.
Associations between incidence of infantile eczema, maternal helminth infection and treatment with albendazole during pregnancy
| Incidence rates for eczema in infants age
0–15 months* (per 100 person
years) |
||||||||
|---|---|---|---|---|---|---|---|---|
| Maternal helminth infection status |
Mother received placebo |
Mother received albendazole |
Overall |
|||||
| In pregnancy | At delivery | Person years of follow-up | Number of episodes | Rate (95% CI) | Number of episodes | Rate (95% CI) | Number of episodes | Rate (95% CI) |
| None | None | 19.1 | 5 | 53.8 (22.4–129.3) | 9 | 91.4 (47.6–175.7) | 14 | 73.1 (43.3–123.5) |
| None | Any | 2.3 | 2 | 0 | 0 | 0 | 0 | 0 |
| Any | None | 4.1 | 0 | 0 | 6 | 291.4 (130.9–648.7) | 6 | 145.8 (65.5–324.6) |
| Any | Any | 36.8 | 2 | 10.4 (2.6–41.7) | 3 | 17.1 (5.5–52.9) | 5 | 13.6 (5.7–32.7) |
*Data from the preliminary study. Multiple events occurring in the same infants are included in these crude rates. A more detailed analysis, allowing for multiple episodes using a random effects model, is presented elsewhere [23].